KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Cash & Equivalents (2020 - 2025)

Oscar Health (OSCR) has disclosed Cash & Equivalents for 6 consecutive years, with $2.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 81.65% year-over-year to $2.8 billion, compared with a TTM value of $2.8 billion through Dec 2025, up 81.65%, and an annual FY2025 reading of $2.8 billion, up 81.65% over the prior year.
  • Cash & Equivalents was $2.8 billion for Q4 2025 at Oscar Health, up from $2.1 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $2.8 billion in Q4 2025 and bottomed at $1.1 billion in Q3 2021.
  • Average Cash & Equivalents over 5 years is $1.9 billion, with a median of $2.1 billion recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 372.08% in 2021, then plummeted 33.75% in 2023.
  • Year by year, Cash & Equivalents stood at $1.1 billion in 2021, then surged by 41.18% to $1.6 billion in 2022, then increased by 20.0% to $1.9 billion in 2023, then decreased by 18.35% to $1.5 billion in 2024, then surged by 81.65% to $2.8 billion in 2025.
  • Business Quant data shows Cash & Equivalents for OSCR at $2.8 billion in Q4 2025, $2.1 billion in Q3 2025, and $2.6 billion in Q2 2025.